The EAEU's common pharmaceutical market built on Union rules offers major opportunities for oncology drug makers and supports higher sales and margins, EEC Minister for Technical Regulation Aleksandr Subbotin said at the Drug Safety forum during SPIEF 2026. Source: Eurasian Economic Commission (EEC).
He noted that Union law provides accelerated and simplified registration for breakthrough medicines, including oncology products. One third of the 15 high-tech drugs registered under EAEU rules are anti-tumour agents, including those based on genetically modified human leukocytes.
Using real-world clinical data in Union countries alongside leading pharmaceutical powers, Subbotin said, shortens development timelines and improves the effectiveness of research on marketed drugs. Broader use of artificial intelligence in pharma, he added, supports sustainable growth of the common market and drives innovation in oncology and other medical fields.
Subbotin invited forum participants to an expert panel on breakthrough therapy medicines that the EEC will hold on 10 June 2026. Drug Safety is an annual flagship event bringing together government, business and civil society to shape the direction of pharmaceutical supply.
